Close Menu

No National Approach

As the US has no national SARS-CoV-2 genome sequencing program, it is unable to spot where in the country a recently identified viral strain may be circulating or keep an eye out for new, emerging viral variants, the New York Times writes.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Italy has held talks with vaccine developers to manufacture mRNA-based SARS-CoV-2 vaccines, according to the Financial Times.

The Associated Press reports US officials are removing restrictions on fetal tissue research that were added during the Trump Administration.

The Biden Administration is investing $1.7 billion to detect and monitor SARS-CoV-2 variants.

In PLOS this week: genome instability in Aicardi-Goutières Syndrome, introduction of SARS-CoV-2 to the Colombian Amazon, and more.